Get started
Author

Laurence T. Rimsky

Observed names: L Rimsky, L T Rimsky, L T Rimsky Phd, L. Rimsky, L. T. Rimsky, LT Rimsky, Laurence Rimsky, Laurence Rimsky-Clarke, Laurence T Rimsky, Rimsky, L.T.
Institution: Janssen (Belgium)
Observed institutions: Université Paris-Sud, Universitat Autònoma de Barcelona, Centre National de la Recherche Scientifique, Howard Hughes Medical Institute, Janssen (Belgium), Inserm, Institut Pasteur, Duke University, Institut Gustave Roussy, IrsiCaixa, Duke Medical Center, Hospital Universitari Germans Trias i Pujol, Triangle Pharmaceuticals, Inc. (United States)
OpenAlex ID: A5111763075
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
1998 · Laurence T. Rimsky, Diane C. Shugars, et al. · Journal of Virology · 426
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
2011 · Jean-Michel Molina, Pedro Cahn, et al. · The Lancet · 412
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
2011 · Calvin J Cohen, Jaime Andrade-Villanueva, et al. · The Lancet · 376
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
2009 · Hilde Azijn, Ilse Tirry, et al. · Antimicrobial Agents and Chemotherapy · 294
Cloning and expression of a cDNA for human thioredoxin.
1988 · E E Wollman, L d'Auriol, et al. · Journal of Biological Chemistry · 242
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein
1988 · Laurence Rimsky, Joachim Hauber, et al. · Nature · 212
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.
1989 · S M Hanly, L T Rimsky, et al. · Genes & Development · 195
PDF
Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis
2011 · Laurence Rimsky, Johan Vingerhoets, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 176
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
2012 · Calvin J. Cohen, Jean-Michel Molina, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 160
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
2012 · Calvin J. Cohen, Jean-Michel Molina, et al. · AIDS · 143
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
2009 · Anton L Pozniak, Javier Morales-Ramirez, et al. · AIDS · 118
The Inhibitory Activity of an HIV Type 1 Peptide Correlates with Its Ability to Interact with a Leucine Zipper Structure
1995 · Carl Wild, Teresa Greenwell, et al. · AIDS Research and Human Retroviruses · 103
Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.
1987 · H Wakasugi, L Rimsky, et al. · Proceedings of the National Academy of Sciences · 101
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
1995 · M Girard, B Meignier, et al. · Journal of Virology · 95
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors
2009 · Lotke Tambuyzer, Hilde Azijn, et al. · Antiviral Therapy · 93
PDF
The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness
2011 · Rima Kulkarni, Kerim Babaoglu, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 88
Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins
1989 · E Böhnlein, M Siekevitz, et al. · Journal of Virology · 85
PDF
Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator
1989 · Laurence Rimsky, Madeleine Due Dodon, et al. · Nature · 73
Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.
1986 · L Rimsky, H Wakasugi, et al. · The Journal of Immunology · 63
Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model
2003 · Béatrice Seignères, Perrine Martin, et al. · Antimicrobial Agents and Chemotherapy · 54
Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial
2011 · Aimee Wilkin, Anton L. Pozniak, et al. · AIDS Research and Human Retroviruses · 50
96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials
2013 · Laurence Rimsky, Veerle Van Eygen, et al. · Antiviral Therapy · 46
PDF
Rex transregulation of human T-cell leukemia virus type II gene expression
1991 · J H Kim, P A Kaufman, et al. · Journal of Virology · 35
Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response
2012 · Johan Vingerhoets, Laurence Rimsky, et al. · Antiviral Therapy · 34
PDF
Week 96 analysis of rilpivirine or efavirenz in HIV ‐1‐infected patients with baseline viral load ≤ 100 000 copies/m L in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials
2013 · J‐M Molina, N Clumeck, et al. · HIV Medicine · 31
PDF
Works count: 51
Citation count: 3,978
H-index: 28
I10-index: 37
Year
Topic
Type